Kathia Ortiz-Cantillo, MD
Critical Care Medicine · Savannah, GANPI 1841301140
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,308 of the $7,526 with a category attached, or 70.5%. 27 manufacturers reported payments, led by Olympus Corporation Of The Americas at 26.6% of the total. Among critical care medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- AstraZeneca$931
- GSK$727
- Insmed, Inc.$487
- Boehringer Ingelheim$484
- Electromed, Inc.$461
- plus $2K from 21 others
What the payments were for
- Travel & lodging$1,85725%
- Food & beverage$5,30871%
- Education$3625%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 16 | $2,005 |
| AstraZeneca(2 entities) | 50 | $931 |
| GSK | 46 | $727 |
| Insmed, Inc. | 17 | $487 |
| Boehringer Ingelheim | 24 | $484 |
| Electromed, Inc. | 17 | $461 |
| Philips North America LLC | 20 | $365 |
| Harmony Biosciences LLC | 7 | $331 |
| Grifols USA, LLC | 10 | $204 |
| Mallinckrodt Hospital Products Inc. | 6 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $160 |
| Baxter Healthcare | 7 | $153 |
| Regeneron Healthcare Solutions, Inc. | 6 | $144 |
| Mylan Specialty L.p. | 7 | $144 |
| Amgen | 7 | $129 |
| United Therapeutics Corporation | 2 | $125 |
| Inogen, Inc. | 7 | $110 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Actelion Pharmaceuticals US, Inc. | 3 | $53 |
| Itamar Medical Inc | 1 | $51 |
| Sanofi | 2 | $51 |
| Jazz Pharmaceuticals Inc. | 2 | $43 |
| AbbVie | 2 | $33 |
| Optinose US, Inc. | 1 | $26 |
| Verona Pharma, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Viatris Specialty LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Olympus Respiratory Accessories$1,726
- Olympus Capital Accessories$1,726
- Olympus EBUS Bronchoscopes$1,138
- Olympus Bronchoscopes$587
- Arikayce$125
- OFEV$104
How this compares
$7,526 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 18 | $314,789 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 217 | $296,127 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $105,513 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $70,583 |
| NucalaMepolizumab | 12 | $42,501 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $27,960 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $27,615 |
| OzempicSemaglutide | 19 | $16,277 |
| Spiriva RespimatTiotropium Bromide | 21 | $15,172 |
| Arnuity ElliptaFluticasone Furoate | 32 | $14,847 |
| Spiriva HandihalerTiotropium Bromide | 11 | $14,015 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $11,591 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 45 | $9,085 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 173 | $7,395 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $7,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $727 | $409,051341 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $484 | $337,20750 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere | $931 | $117,104100 claims |
| Grifols USA, LLCProlastin C | $204 | $70,58312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Savannah
- Craig SchuringSavannah$12K
- Casey MorrisSavannah$5K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
- Matthew SchmittAtlanta$32K
- Prasad GarimellaBraselton$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.